Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

FDA Approves Rhapsido®: A New Hope for Chronic Spontaneous Urticaria Patients Novartis' Rhapsido® gains FDA approval as the first oral BTK inhibitor for chronic spontaneous urticaria, promising quick relief for patients.

FDA Approves Rhapsido®: A New Hope for Chronic Spontaneous Urticaria Patients #None #Novartis #CSU #Rhapsido